Release of HMGB1 in response to pro-apoptotic glioma killing strategies: efficacy and neurotoxicity

PURPOSE: In preparation for a Phase I clinical trial utilizing a combined cytotoxic/immunotherapeutic strategy using adenoviruses expressing Flt3L (Ad-Flt3L) and thymidine kinase (Ad-TK) to treat glioblastoma (GBM), we tested the hypothesis that Ad-TK+GCV would be the optimal tumor killing agent in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Candolfi, Marianela, Yagiz, Kader, Foulad, David, Alzadeh, Gabrielle E, Tesarfreund, Matthew, Muhammad, AKM G, Puntel, Mariana, Kroeger, Kurt M, Liu, Chunyan, Lee, Sharon, Curtin, James F, King, Gwendalyn D, Lerner, Jonathan, Sato, Katsuaki, Mineharu, Yohei, Xiong, Weidong, Lowenstein, Pedro R, Castro, Maria G
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2769255/
https://ncbi.nlm.nih.gov/pubmed/19570774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-0155
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak